Montal, Robert
Andreu-Oller, Carmen
Bassaganyas, Laia
Esteban-Fabró, Roger
Moran, Sebastián
Montironi, Carla
Moeini, Agrin
Pinyol, Roser
Peix, Judit
Cabellos, Laia
Villanueva, Augusto
Sia, Daniela
Mazzaferro, Vincenzo
Esteller, Manel
Llovet, Josep M.
Article History
Received: 15 April 2019
Revised: 12 June 2019
Accepted: 14 June 2019
First Online: 9 July 2019
Competing interests
: J.M.L. is receiving research support from Bayer HealthCare Pharmaceuticals, Eisai Inc, Bristol-Myers Squibb and Ipsen, and consulting fees from Bayer HealthCare Pharmaceuticals, Eli Lilly, Bristol-Myers Squibb, Eisai Inc, Celsion Corporation, Exelixis, Merck, Ipsen, Glycotest, Navigant, Leerink Swann LLC, Midatech Ltd, Fortress Biotech, Sprink Pharmaceuticals, Nucleix and Can-Fite Biopharma. Manel Esteller reports grants from Ferrer International SA and Quimatryx. Augusto Villanueva reports personal fees from Exelixis, Health Advances LLC, GroupH, Gerson Lehrman Group and Exact Sciences.
: The institutional review boards of the participating centres (IRCCS Istituto Nazionale Tumori [Milan] and Hospital Clínic [Barcelona]) approved the study. Patients provided written informed consent. The study was conducted in accordance with International Standards of Good Clinical Practice and the Declaration of Helsinki.
: Robert Montal is supported by a FSEOM-Boehringer Ingelheim Grant. Carmen Andreu-Oller has received financial support through the “la Caixa” INPhINIT Fellowship Grant for Doctoral studies at Spanish Research Centres of Excellence, from “la Caixa” Banking Foundation (ID 100010434), fellowship code (LCF/BQ/IN17/11620024). Laia Bassaganyas was supported by Beatriu de Pinós grant from Agència de Gestió d’Ajuts Universitaris i de Recerca (AGAUR, Generalitat de Catalunya). Roger Esteban-Fabró is supported by MICINN/MINECO (BES-2017-081286). Carla Montironi is a recipient of Josep Font grant from Hospital Clinic de Barcelona. Roser Pinyol is funded by European Commission/Horizon 2020 Program (HEPCAR, Ref. 667273-2). Judit Peix is supported by Centro de Investigacion Biomedica en Red de Enfermedades Hepaticas y Digestivas (CIBERehd)—ISCIII. Augusto Villanueva is supported by U.S. Department of Defense (CA150272P3) and Tisch Cancer Institute (Cancer Center Grant P30-CA196521). Daniela Sia is supported by the Gilead Sciences Research Scholar Program in Liver Disease. Vincenzo Mazzaferro is supported by grants from Associazione Italiana per la Ricerca sul Cancro and the Oncology Research Project of the Italian Ministry of Health. Manel Esteller is supported by the Department of Health PERIS project SLT/002/16/00374 and AGAUR projects 2017SGR1080, 2014SGR633 and 2009SGR1315 of the Catalan Government (Generalitat de Catalunya); the Spanish Institute of Health Carlos III (ISCIII) with project DTS16/00153 and the Integrated Project of Excellence PIE13/00022 (ONCOPROFILE), and the Ministerio de Economía y Competitividad (MINECO) grant SAF2014-55000-R, co-financed by the European Development Regional Fund “A way to achieve Europe” (ERDF); CIBER 2016 CB16/12/00312 (CIBERONC); the Cellex Foundation; “la Caixa” Banking Foundation (LCF/PR/PR15/11100003). Josep M. Llovet is supported by National Cancer Institute (P30-CA196521), U.S. Department of Defense (CA150272P3), European Commission/Horizon 2020 Program (HEPCAR, Ref. 667273-2), EIT Health (CRISH2, Ref. 18053), Accelerator Award (CRUCK, AECC and AIRC) (HUNTER, Ref. C9380/A26813), Samuel Waxman Cancer Research Foundation, Centro de Investigacion Biomedica en Red de Enfermedades Hepaticas y Digestivas (CIBERehd)—ISCIII, Spanish National Health Institute (SAF2016-76390) and the Generalitat de Catalunya/AGAUR (SGR-1358).
: Data from the internal HEPTROMIC cohort are stored in the Gene Expression Omnibus (GEO) repository: whole-genome expression (GSE63898) and DNA methylation (GSE56588). Whole-exome sequencing was deposited in the EGA database (accessions EGAS00001000217, EGAS00001000679 and EGAS00001001002) and the ICGC data portal. Data from the external publicly available TCGA cohort were downloaded from ExternalRef removed.
: This work is published under the standard license to publish agreement. After 12 months the work will become freely available and the license terms will switch to a Creative Commons Attribution 4.0 International (CC BY 4.0).